Meeting
2022 ASCO Annual Meeting
Phase 1b study of GS-3583, a novel FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.
Authors
Anthony W. Tolcher
Next Oncology, San Antonio, TX
Anthony W. Tolcher , Joshua Brody , Nishanthan Rajakumaraswamy , Nehal J. Lakhani , Michelle R. Kuhne , Torsten Trowe , Deyuan Jiang , Anees Dauki , Shivaani Kummar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04747470
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2566)
DOI
10.1200/JCO.2022.40.16_suppl.2566
Abstract #
2566
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2023 ASCO Annual Meeting
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
First Author: Mirella Nardo
Poster
2023 ASCO Annual Meeting
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
First Author: Manish R. Patel
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
First Author: Anwaar Saeed